Organogenesis Holdings (ORGO) Capital Expenditures Growth (3y) (2021 - 2026)
Organogenesis Holdings (ORGO) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | -47.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.26% |
| Mar 31, 2026 | 16.57% |
| Dec 31, 2025 | -24.14% |
| Sep 30, 2025 | -40.11% |
| Jun 30, 2025 | -30.78% |
| Mar 31, 2025 | 24.72% |
| Dec 31, 2024 | -13.69% |
| Sep 30, 2024 | -46.42% |
| Jun 30, 2024 | -8.53% |
| Mar 31, 2024 | -45.87% |
| Dec 31, 2023 | -15.03% |
| Sep 30, 2023 | 48.51% |
| Jun 30, 2023 | -26.99% |
| Mar 31, 2023 | -22.36% |
| Dec 31, 2022 | 45.52% |
| Sep 30, 2022 | 101.31% |
| Jun 30, 2022 | 127.32% |
| Mar 31, 2022 | 80.66% |
| Dec 31, 2021 | 81.21% |
| Sep 30, 2021 | 161.13% |